Arcus Biosciences Total Assets 2017-2022 | RCUS

Arcus Biosciences total assets from 2017 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Arcus Biosciences Annual Total Assets
(Millions of US $)
2021 $1,592
2020 $772
2019 $203
2018 $275
2017 $190
2016 $0
Arcus Biosciences Quarterly Total Assets
(Millions of US $)
2022-09-30 $1,394
2022-06-30 $1,477
2022-03-31 $1,543
2021-12-31 $1,592
2021-09-30 $839
2021-06-30 $899
2021-03-31 $935
2020-12-31 $772
2020-09-30 $811
2020-06-30 $481
2020-03-31 $176
2019-12-31 $203
2019-09-30 $217
2019-06-30 $239
2019-03-31 $259
2018-12-31 $275
2018-09-30 $287
2018-06-30 $294
2018-03-31 $305
2017-12-31 $190
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.526B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.463B 9.68
GSK (GSK) United Kingdom $72.345B 9.55
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.197B 19.11
Ginkgo Bioworks Holdings (DNA) United States $3.802B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Biohaven (BHVN) United States $1.232B 0.00
Emergent Biosolutions (EBS) United States $0.683B 5.37
ADC Therapeutics SA (ADCT) Switzerland $0.350B 0.00
Ambrx Biopharma (AMAM) United States $0.069B 0.00
Enzo Biochem (ENZ) United States $0.066B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00
Gelesis Holdings (GLS) United States $0.025B 0.00